Firmagon Európai Unió - magyar - EMA (European Medicines Agency)

firmagon

ferring pharmaceuticals a/s - degarelixet - prosztatikus daganatok - endokrin terápia - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Degarelix Accord Európai Unió - magyar - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - prosztatikus daganatok - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Camcevi Európai Unió - magyar - EMA (European Medicines Agency)

camcevi

accord healthcare s.l.u. - leuprorelin mesilate - prosztatikus daganatok - endokrin terápia - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Orgovyx Európai Unió - magyar - EMA (European Medicines Agency)

orgovyx

accord healthcare s.l.u. - relugolix - prosztatikus daganatok - endokrin terápia - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.